Hot Stocks

Hot stocks are not about hype. They emerge when powerful themes, policy shifts, and capital flows converge. InvestorPlace analysts track fast-moving market narratives, especially in technology, AI, and infrastructure, to identify stocks drawing outsized attention and explain what is really driving those moves.

FedEx Flies, Discover Dives — Thursday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Both beat earnings estimates, but then went separate ways.

Covidien Follows Abbott With a Pharma Spin-Off

By Barry Cohen, Health Care Writer
Could Sanofi, Novartis or GlaxoSmithKline be next to separate pharmaceutical development into a stand-alone company?

A Double Whammy for Homebuilders

By Ethan Roberts, InvestorPlace Contributor
A downgrade of TOL and LEN, then a downbeat announcement from the National Association of Realtors raise big questions.

Gold, Silver Continue Their Slump

By Andrew Burger, InvestorPlace Contributor
Positive economic data can't get precious metals rallying, as European concerns continue their grip on risk assets.

The ‘Other Berkshire’ Worth a Closer Look

By Lawrence Meyers, InvestorPlace Contributor
Its operation can be difficult to grasp, but if you know what to look for, you'll get a better understanding for this smartly run company.

Amazon Investors Should Wait Out the Storm

By Kevin Kelleher, Technology & Markets Contributor
While the Kindle Fire is cramping Amazon's profit margins, eventual tablet success could further improve its standing as the premier online retailer.

Green Mountain Looks Like a Fading Fad

By Will Ashworth, InvestorPlace Contributor
Green Mountain is off more than 20% this week, and stiff competition makes it look unlikely that GMCR stock will ever reach its $100-plus zenith again.

Dreary Day for Gold, Oil — Wednesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Gold breaks through its key $1,600 per ounce level

Groupon’s Analysts Not Too Thrilled

By Tom Taulli, InvestorPlace Contributor
Excited traders pushed Groupon stock up 9% Tuesday, but its quiet period ended Wednesday with an unexpectedly dull roar from analysts.

Avon Surges on CEO Change — But AVP Stock Still Shaky

By Jeff Reeves
AVP stock might look good after a leadership change and with a 5% dividend, but Andrea Jung's replacement will be fighting SEC investigations, other issues.

Gold Breaks 200-Day MA, Silver Plummeting

By Andrew Burger, InvestorPlace Contributor
Gold fell below the $1,600 mark Wednesday morning and silver also was hammered on euro zone and U.S. monetary policy worries.

Why Diamond Foods’ Stock Has Gone Nuts

By Will Ashworth, InvestorPlace Contributor
Diamond Foods' has become a trader magnet after word of a massive deal -- and then an audit investigation -- turned DMND stock on its head. Is this nut worth cracking?

Pfizer Delivers Early Holiday Gifts to Shareholders

By Barry Cohen, Health Care Writer
The company brings holiday cheer with its new stock repurchase program and dividend boost.

Make Money in Timeshares — By Investing

By Jon Markman, Editor, Trader's Advantage and CounterPoint Options
No get-rich-quick schemes with this timeshare buy -- just a solidly managed company at the right price.

Retail Stocks Follow Best Buy’s Lead — Tuesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
BBY's squeezed margins, lackluster retail sales growth weigh on stocks overall

Spotify Turns Up Pressure On Pandora’s Prospects

By Tom Taulli, InvestorPlace Contributor
In the apparent two-horse race, Spotify is turning up the pressure on Pandora.

Gold, Silver, Miners Continue to Fall Tuesday

By Andrew Burger, InvestorPlace Contributor
While gold and silver were slightly down Tuesday morning, several miners were taking solid losses on the day. Pan American Silver stood out with almost 2% gains.

Can Meg Whitman’s ‘Buzz’ Buy Time to Revive Hewlett-Packard?

By Susan J. Aluise, Aviation, Auto & Transportation Writer
Considering the impatient board presiding over HPQ, Meg Whitman's style might count for just as much as substance.

Abbott Labs Spinoff Looks Like the Right Move

By Barry Cohen, Health Care Writer
Shareholders would likely be better served by the company's prescription drug business standing alone. Here's why.
Load More Articles